【江北嘴发布】智飞生物又获发明专利证书

Core Viewpoint - Zhifei Biological has recently obtained a patent for a stable adenoviral vector freeze-dried preparation and its application, which will enhance the company's intellectual property protection and core competitiveness [1] Group 1: Patent Acquisition - Zhifei Biological and its subsidiaries have received the invention patent certificate for "a stable adenoviral vector freeze-dried preparation and its application" [1] - The patent was issued by the National Intellectual Property Administration of the People's Republic of China, with application number ZL202311377259.3 and certificate number 8546593 [1] - The patent application date was October 24, 2023, and the authorization announcement date is December 5, 2025 [1] Group 2: Implications of the Patent - The patent acquisition is a result of the company's independent research and development efforts [1] - This patent will be applied in relevant research and development projects, promoting technological innovation [1] - The achievement of this patent is expected to enhance the company's core competitiveness by leveraging its independent intellectual property advantages [1]